[Therapeutic use of amiloride and its combinations with hydrochlorothiazide and furosemide in chronic circulatory insufficiency].
The clinical pharmacology of the diuretic amyloride was studied in 60 patients suffering from circulatory insufficiency of various origin. Midamor and moduretic of the "Merck" firm (USA) were used in a dose of 1 to 4 tablets. The duration of treatment was from 3 days to 18 months. It was found that under the effect of amyloride natriuresis increases moderately in patients with circulatory insufficiency with no simultaneous increase in the loss of potassium with the urine. As the circulatory insufficiency becomes more severe, the natriuretic and potassium-saving effect of the drug diminishes. Amyloride potentiates the diuretic and natriuretic effect of furosemide and hydrochlorothiazide well without increasing kaliuresis. In patients in whom the disease is less severe, two-week treatment with amyloride leads to an authentic increase in the total metabolic potassium in the organism. The patients tolerate the drug well. It is recommended for wide clinical use.
D000328:Adult; D000368:Aged; D000584:Amiloride / Q000008:administration & dosage / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000188:drug therapy*; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D004231:Diuresis / Q000187:drug effects; D004338:Drug Combinations; D004341:Drug Evaluation; D004357:Drug Synergism; D005260:Female; D005665:Furosemide / Q000627:therapeutic use*; D006801:Humans; D006852:Hydrochlorothiazide / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009318:Natriuresis / Q000187:drug effects; D011188:Potassium / Q000652:urine; D011719:Pyrazines / Q000627:therapeutic use*; D013997:Time Factors
D004338:Drug Combinations; D011719:Pyrazines; D006852:Hydrochlorothiazide; D000584:Amiloride; D005665:Furosemide; D011188:Potassium
Terapevticheskoe primenenie amilorida i ego sochetaniĭ s gidrokhlortiazidom i furosemidom u bol'nykh s khronicheskoĭ nedostatochnost'iu krovoobrashcheniia.